Avacta Share Discussion Threads

[toffeeman] 03/9/2018 13:39

Hi (again) Longshanks yet another stock we have in common :)

[escapetohome] 31/8/2018 13:33

Just i said.

Strong buy!

Company for sale!!!!

[dave4545] 31/8/2018 13:03

Not getting tired of all these increases in price here. Clearly there is a 100k buyer and the mm's are struggling to get any selling of size to match it.

[1i1i1i] 31/8/2018 12:41

Another delayed 100,000 buy gone through, looking set for a great end of year run.

[dave4545] 31/8/2018 10:29

Thanks longshanks.

Still a squeeze, there is so little stock on offer, they keep trying to shake it but nobody is really selling down these levels

[longshanks] 31/8/2018 10:18

According to their website they held 23.7% in December 2017. Looks like they took part in the placing but have reduced their overall percentage holding.

[dave4545] 31/8/2018 10:05

If I have that correct a certain IP Group plc have gone from nothing to 18% here

wow

[dave4545] 30/8/2018 11:15

Even better now cannot even buy 1000 shares online

[dave4545] 30/8/2018 11:05

Yep looks great, another delayed 100k buy shows up as I write this

[1i1i1i] 30/8/2018 10:54

25-26p now, looking good Dave. The expected announcements to follow from September onwards.

[dave4545] 30/8/2018 10:00

Looks really good 23-25p but online bid 24.25p now

[dave4545] 30/8/2018 09:43

Bounce time, little shake earlier failed and offer now is up to 24.4p and well bid as always here

[dave4545] 29/8/2018 14:58

mm's bidding over mid price again

Online spread is 23.65-23.75p...looks a lot better than 23-24p monitor spread

[hampton58] 29/8/2018 09:41

This particular sector is in the news almost on a daily basis, JV's being signed with upfront payments and future royalty payments totalling 100' of millions . Life science involved in making alternatives to Anti Bodies is one of the hottest M&A areas at the moment.Affimer will be highlighted at conference in Boston .The company successfully raised the capital , they are moving forward at great pace and are attracting interest outside UK.Gentlemen ( and Ladies) purchase at these levels and you will look very clever in Q4

[swizz] 28/8/2018 16:11

Lol, was just thinking the very same thing a few moments ago,...GL S

[dave4545] 24/8/2018 15:39

boom 100k pays 25.9p

[dave4545] 23/8/2018 16:17

Looks solid

24.6-25.2p

Online 24.8-24.96p

[1i1i1i] 23/8/2018 08:53

Worth a reminder from 30th July, obviously we have £11m more in the bank now.CURRENT TRADING AND OUTLOOKThe interim results released on 16 April 2018 demonstrated the continued progress that the Company has made. The results showed revenues increased 16 per cent to GBP1.5m (GBP1.3m FY17) and, at 31 January 2018, cash balances were GBP8.3 million. With regards to the Affimer Therapeutics business, Avacta has made good progress with in-house programmes, the lead PD-L1 programme is on-track to deliver several key pre-clinical milestones in 2018 and there is continued platform validation and de-risking through completion of a number of in-vitro data packages. The Company has made solid progress with a number of partners such as partners Moderna, Glythera Ltd and FIT Biotech (FITBIO:FN Finland). There are ongoing collaborations with Memorial Sloan Kettering Cancer Centre and with OncoSec (NASDAQ: ONCS) and recently the Company announced a drug development partnership based on a ground-breaking co-invention with Tufts University School of Medicine in Boston, US. This partnership focuses on an entirely novel approach to making drug conjugates combining Avacta's Affimer technology with drugs developed by Professor William Bachovchin, Professor of Chemical and Molecular Biology at Tufts. Avacta is in discussions with multiple pharma and biotech regarding Affimer therapeutics opportunities. The pipeline of opportunities continues to grow across multiple applications.With regards to Affimer research and diagnostics reagents, the focus is on licensing opportunities for reagents in non-therapeutic markets: progress has been made with multiple third-party technology evaluations and Avacta is expecting further licensing deals in 2018. In addition, there has been strong growth in public validations of Affimer technology by third parties. This includes a record period for publication of third party peer reviewed scientific papers using Affimers as well as public support by likes of Covance and Heptares.Since 31 January 2018, Avacta has made progress in a second therapeutic programme, a LAG-3 inhibitor, such that the Group is confident to leap-frog the planned clinical trials for a PD-L1 inhibitor on its own and, on a similar timescale, aim for first-time-in-human clinical data for a PD-L1/LAG-3 bispecific therapy - a potentially much more valuable asset.The Company is working with partners to demonstrate the potential of the Affimer technology in other therapeutic areas. In one such area, gene delivery, the Company has received a great deal of interest as a result of, the Directors believe, the technical benefits of the Affimer technology for this application. Moderna, Oncosec and FIT Biotech are all gene delivery collaborations. Moderna is evaluating Affimers against multiple targets and the Company expects Moderna to make a decision whether to develop these Affimers further before the end of 2018. In May 2018 the Company announced that its research collaboration with FIT Biotech had successfully completed a proof-of-concept gene delivery study with very encouraging data, showing sustained production of Affimer molecules by the muscle tissue of mice following a single dose of the Affimer DNA using the FIT technology.With the growing body of data generated in-house and through collaborations, the Company expects that it will have sufficient evidence of the performance of Affimer therapeutics to secure at least one significant development partnership including an upfront payment with a significant pharma partner in the next two years before it reaches the clinic itself with its lead in-house programme. The Company expects that, in due course, clinical data from its in-house programmes will be seen as a major de-risking point that will make deal-making easier and deal sizes larger.

[dave4545] 23/8/2018 08:27

Cannot even buy 2500 online now at 24.6p

Ready to push on above the placing price again

[dave4545] 23/8/2018 08:18

24-24.6p

Judging by the online quotes it could easily kick on again on any support

Online it's full offer to buy and 24.25p bid which is a nice premium on that tight spread.

[dave4545] 22/8/2018 17:07

This is just the start...clearly overhang cleared now it's back to mm's v the pi's again

[1i1i1i] 22/8/2018 15:05

Up over 10% now!

[danatkins] 22/8/2018 12:07

I'd be happy with 90p. Time will tell of course

[escapetohome] 22/8/2018 11:21

Not surprised.

COMPANY FOR SALE SIGN HOISTED.